No Pill, No Shot, No Patch: The People Left Behind by the Cocaine Treatment Desert

When Darnell — 34, from South Phoenix — finally decided he was done with cocaine, he called three treatment programs in the Phoenix metro. Two had waitlists of three to four weeks. The third took his insurance, which was AHCCCS, but the counselor who answered the phone told him upfront: “We don’t have medication for that. We do therapy.”

Darnell knew this already. He’d been through treatment once before, at 29, and come back out the other side into a relapse. He went back in. “It’s not like opioids,” he said, in a conversation shared by his peer support specialist (with his permission and with his name changed). “Nobody’s handing you a pill that makes the craving go away. You just have to white-knuckle it, and then go to your appointment, and then white-knuckle it some more.”

He is correct. There are zero FDA-approved medications for cocaine use disorder.

This is not for lack of trying. Researchers have studied dozens of candidate compounds — modafinil, disulfiram, topiramate, bupropion, prescription amphetamines as substitution therapy, gabapentin, N-acetylcysteine — with consistent results that range from modest effects to no significant benefit over placebo in well-powered randomized controlled trials. The cocaine-altered brain — dopamine transporter downregulation, orbitofrontal cortex dysfunction, glutamate signaling disruption — has resisted every pharmacological intervention researchers have thrown at it.

The one intervention with genuine evidence is contingency management (CM): a behavioral approach in which patients earn vouchers or small cash rewards for negative drug screens. Multiple meta-analyses confirm CM produces meaningful reductions in cocaine use and improvements in treatment retention. It works.

The problem is the federal reimbursement cap. Under the SUPPORT Act’s interpretation, Medicaid reimbursement for CM incentives is capped at approximately $599 per year per patient. A properly powered CM program for cocaine use disorder costs more than that. In states where Medicaid is the primary payer for people who need this treatment most, the cap structurally prevents CM from scaling to the populations that need it.

For Darnell, this plays out concretely. His three-times-a-week outpatient program offers a version of CM — a $5 gift card for a negative screen. “It’s not nothing,” he said. “But when you’re 48 hours out from a binge and your brain is telling you that what you need is right down the street, five dollars is not what’s standing between you and doing it.”

What stands between him and doing it, he says, is his peer support specialist — someone who has their own history with cocaine and who calls him when the program flags a missed appointment. Human relationship, mutual accountability, lived experience applied in real time. Not medication. Not a reimbursable pharmacological intervention. A person.

Peer recovery support is the best tool the cocaine treatment system currently has. It is also the category of support least likely to be covered by insurance, least likely to be funded by a shrinking grant environment, and most dependent on organizations that are perpetually one funding cycle away from cutting staff.

Darnell has been clean for fourteen months. He gives the credit to his specialist, to his own determination, and to the fact that he didn’t use alone — that there was someone who noticed when he went quiet. “If I’d had to go through that without him,” he said, “I don’t think I’d still be here.”

The cocaine treatment desert is not an accident. It reflects decades of research funding that followed the opioid crisis because opioids were killing more people more visibly. The populations disproportionately affected by cocaine use disorder — Black and Latino men, in particular — have always had less political representation in the rooms where treatment research priorities are set. The absence of an FDA-approved medication is not a neutral fact. It is the outcome of choices about where to look.

It reflects decades of research funding that followed the opioid crisis because opioids were killing more people more visibly.

---

The Rize Newsroom covers stimulant use disorder and treatment access in the treatment and recovery and lived experience sections. For treatment facility search, visit /find-help.